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Abstract: MRI-targeted biopsy is a promising technique that offers an improved detection of clinically 
significant prostate cancer over standard non-targeted biopsy. It is established that prostate MRI is of use in 
both the primary and repeat biopsy setting for the detection of significant prostate cancer. There are three 
approaches to targeting biopsies to areas of interest seen on prostate MRI. They each rely on the acquisition 
and reporting of a diagnostic quality multi-parametric MRI scan used to identify areas of interest, and the 
subsequent use of those diagnostic quality images in combination with real-time images of the prostate 
during the biopsy procedure. The three techniques are: visual registration of the MRI images with a real-
time ultrasound image; software-assisted fusion of the MRI images and the real-time ultrasound images, and 
in-bore biopsy, which requires registration of a diagnostic quality MRI scan with a real time interventional 
MRI image. In this paper we compare the three techniques and evaluate those studies where there is a direct 
comparison of more than one MRI-targeting technique. PubMed was searched from inception to November 
2016 using the search terms (cognitive registration OR visual registration OR fusion biopsy OR in-bore 
biopsy OR targeted biopsy) AND (prostate cancer OR prostate adenocarcinoma OR prostate carcinoma 
OR prostatic carcinoma OR prostatic adenocarcinoma) AND (MRI OR NMR OR magnetic resonance 
imaging OR mpMRI OR multiparametric MRI). The initial search included 731 abstracts. Eleven full text 
papers directly compared two or more techniques of MRI-targeting, and were selected for inclusion. The 
detection of clinically significant prostate cancer varied from 0% to 93.3% for visual registration, 23.2% to 
100% for software-assisted registration and 29% to 80% for in-bore biopsy. Detection rates for clinically 
significant cancer are dependent on the prevalence of cancer within the population biopsied, which in turn 
is determined by the selection criteria [biopsy naïve, previous negative biopsy, prostate specific antigen 
(PSA) selection criteria, presence of a lesion on MRI]. Cancer detection rates varied more between study 
populations than between biopsy approaches. Currently there is no consensus on which type of MRI-
targeted biopsy performs better in a given setting. Although there have been studies supporting each of 
the three techniques, substantial differences in methodology and reporting the findings make it difficult to 
reliably compare their outcomes.
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Introduction
The current standard technique for prostate cancer detection 
in men with a high prostate specific antigen (PSA) or an 
abnormal finding on digital rectal examination (DRE) is a 
10–12 core trans-rectal ultrasound-guided biopsy (TRUS-GB).
The use of a standardized 6-core biopsy over an approach 
targeting lesions visible on ultrasound was first described 
by Hodge and colleagues in 1989 (1). Cancer was found 
in 83 men (62%), and random and directed biopsies were 
done in 57 men. Of those 57 men the biopsy results were 
in agreement in 49 men (86%), whilst in 5 men (9%) 
random systematic biopsies found cancer and in 3 men (5%) 
directed biopsies found cancer missed on systematic biopsy. 
Although the original paper suggesting combining the 
use of systematic biopsies with targeted to biopsies to any 
hypoechoic areas not sampled by systematic biopsy, it became 
common practice to carry out systematic biopsy alone. 
Over time, the number of cores included in systematic 
biopsies increased, so that many take 10–12 cores (2). This 
systematic technique has led to an increase in the detection 
of low-volume and low-risk disease.
Needle biopsy of the prostate is an invasive procedure, 
which can be associated with complications (including 
bleeding, pain, and infection) and it is therefore important 
to maximize the diagnostic information gained. 
Moreover, standard TRUS guided biopsy is highly 
operator-dependent and is systematically poor at sampling 
tumors of the anterior part of the prostate, as well as the 
midline and extreme base. In addition, random error 
can result in tumors in the peripheral zone being missed 
or undersampled (3). This combination of random and 
systematic error explains the low values of sensitivity for 
cancer detection of systematic biopsy (3), which can also 
lead to a risk of pathological upgrading later on, seen in up 
to 40% of men at radical prostatectomy (4).
The European Association of Urology advise performing 
a multiparametric magnetic resonance imaging (mpMRI) 
study when initial standard biopsy results are negative but 
the suspicion of prostate cancer persists (2). This has been 
echoed by a joint consortium of the American Urology 
Association and the Society of Abdominal Radiology, which 
states that where high quality mpMRI is available, it should 
be strongly considered for men in whom a repeat biopsy is 
considered (5). In addition, the National Comprehensive 
Cancer Network (NCCN) guidelines advise the use of 
mpMRI prior to repeat biopsy, with mpMRI-targeted cores 
to be considered in addition to standard cores (6).
Recent advances in mpMRI [e.g., the combination 
of multiple sequences, such as T2-weighted, diffusion-
weighted imaging (DWI) and dynamic contrast-
enhancement] have improved the sensitivity of mpMRI 
for the detection of clinically significant prostate cancer. 
However, the diagnostic capability of prostate mpMRI is 
inherently dependent on a number of factors including the 
technical acquisition of the mpMRI images, the expertise 
of the radiologist reporting the images, the threshold 
used to define a lesion on mpMRI, and the definition of 
histologically significant prostate cancer (7).
The European Society of Urogenital Radiology 
(ESUR) has published recommendations on how to 
conduct and report an mpMRI study of the prostate (8). 
The ESUR was joined by the American College of 
Radiologists (ACR) when the Prostate Imaging-Reporting 
and Data System (PI-RADS) classification version 2.0 was 
recently updated (9). PI-RADS describes the standards 
for image acquisition and reporting, including the precise 
parameters required to predict the likelihood of significant 
disease using a 1–5 scale. 
A systematic review in 2012 by Moore et al. (10) has 
shown that MRI-guided biopsies in the biopsy naïve 
prostate detect clinically significant prostate cancer in 
an equivalent number of men to standard biopsy. This 
is achieved using fewer biopsies in fewer men, and is 
associated with a reduction in the diagnosis of clinically 
insignificant cancer.
Wegelin et al. recently led a systematic review (11) to 
evaluate whether MRI-guided biopsies have increased 
detection rates of clinically significant prostate cancer 
compared to TRUS-GB, analyzing which MRI-guided 
technique has the highest detection rate. The Authors 
concluded that on a per patient basis MRI-guided biopsies 
had higher detection rates of clinically significant prostate 
cancer compared to TRUS-GB, as MRI-guided biopsies 
missed 10% of significant cancers whilst TRUS-GB missed 
21%. The shift in emphasis between the two reviews shows 
the change in the literature over time, and indicates that the 
diagnostic efficiency of prostate MRI is improving over time. 
In a study of 1,140 men (12) with a raised PSA it was 
shown that the proportion of men with cancer was higher 
among those randomized to mpMRI and MRI-targeted 
biopsy (417/570, 73%) compared to those randomized to 
TRUS-guided biopsy (215/570, 38%). 
In another report of 1,003 men, Muthigi et al. (13) have 
recently reported that software-assisted MRI-targeted 
biopsy rarely missed clinically significant prostate cancer, 
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as only 62 of 1,003 cases (6.2%) were upgraded to clinically 
significant disease by systematic biopsy. 
MRI-targeted biopsy has been shown to significantly 
improve risk stratification by reducing sampling error (14) 
and evidence is accumulating in recommending mpMRI as 
a means of directing either initial or repeat biopsies of the 
prostate, following a previous negative TRUS-GB (15,16).
Some studies of MRI-targeted prostate biopsies 
have significantly higher rates of detection for clinically 
significant cancer, being associated with a higher percentage 
of positive cores and longer maximum cancer core length 
compared to systematic biopsies (10,17). Use of targeted 
cores alone can also reduce the detection of incidental, 
clinically insignificant tumors, although there is no 
widespread agreement that this is the optimal strategy (18).
Types of MRI-targeted biopsy 
According to the Standards of Reporting for MRI-targeted 
Biopsy Studies (START) guidelines (19), an MRI-targeted 
biopsy is defined as a technique where an mpMRI scan is 
used to determine the location of a suspicious target within 
the prostate prior to biopsy.
There are three practical approaches to MRI-targeted 
biopsy: (I) visual registration; (II) software-assisted (fusion) 
registration and (III) direct in-bore biopsy. Currently, there 
is no consensus on whether any one type of MRI-targeted 
biopsy is superior in cancer detection or other areas, 
although visual registration is likely to be the least expensive 
of the three approaches.
In fact, all of these methods have shown the potential 
to address the drawbacks of TRUS-GB (i.e., false-negative 
biopsies and erroneous risk stratification due to under- or 
over-sampling) (20).
Visual registration
In visual registration (also referred to as “cognitive” 
registration in the literature) a suspicious lesion is identified 
on mpMRI by a radiologist prior to biopsy, and then 
targeted using TRUS guidance by the biopsy operator, who 
may be a radiologist, urologist, or other trained operator 
(e.g., nurse practitioner). The information on the location 
of the area of interest may be shown on a diagram (Figure 
1) which can be hand drawn, or created using customized 
software, or snapshots of the areas of interest can be 
saved within the mpMRI file. Some reports will describe 
the location in prose (e.g., between 5 and 7 o’clock), 
although it is generally agreed that a visual report is 
the most helpful. Direct review of the mpMR images 
immediately prior to the biopsy is highly recommended. 
This approach requires a trained operator who is able to 
cognitively transfer the visual information from one format 
to another. MRI-targeted biopsies conducted by visual 
registration have been shown to increase the detection rates 
and accuracy for significant prostate cancer when compared 
with systematic biopsies (17,21).
Software-assisted fusion registration
Suspicious lesions are identified and contoured on the 
mpMR images—together with the whole prostate—prior 
to biopsy. The contours are then uploaded into the fusion 
software platform and converted into a 2D or 3D model, 
which is matched or registered (fusion) with the real-time 
US image during the procedure. This allows the operator 
to identify and target lesions deemed suspicious on mpMRI. 
Figure 1 Hand drawn diagram made by the reporting radiologist 
that can be saved within the MRI file together with snapshots of 
the suspicious areas to be targeted. SV, seminal vesicles.
Patient name:
Snapshot #:
Radiologist:
SV
Base 
(B)
Mid 
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This approach is also called MRI/TRUS fusion biopsy (22).
Three commonly used software-based platforms are 
Artemis (Eigen, Grass Valley, California, USA), Urostation 
(Koelis, LaTronche, France), and UroNav (Philips 
Electronics, Amsterdam, the Netherlands) (23,24).
Registration can be either rigid, where there is a direct 
overlay of the mpMR images over the ultrasound image, or 
elastic. Elastic registration takes into account the difference 
in the shape of the gland between the MRI scan (in supine 
position with or without an endorectal coil) and the 
ultrasound scan (done in lithotomy or left lateral position), 
where the ultrasound probe can deform the prostate. In 
addition, some systems aim to compensate for swelling and 
motion during the procedure. 
MRI/TRUS fusion biopsies have demonstrated detection 
rates superior to systematic biopsies, particularly for higher-
grade disease (25,26).
In-bore biopsy
This technique is carried out within the mpMRI scanner, 
and diagnostic quality images used to identify areas of 
interest are registered with the interventional images (often 
acquired at 1–1.5T). The target lesion is biopsied using 
guidance from serial scans during the procedure (27). 
Different anatomical approaches can be used: transrectal 
(the most common), transperineal and transgluteal. One 
of the main advantages of this technique is the ease of 
registration of two sets of mpMR images acquired in a 
similar position. It is common practice in this approach 
that only a few targeted cores are taken, reducing the 
detection of insignificant tumors. However, this approach 
requires significant additional training for the radiologist 
and time in the MRI scanner, as well as training of the 
biopsy operator. 
A systematic review by Overduin et al. (28) has shown 
that the cancer detection rates of in-bore biopsies range 
from 8% to 59% (median 42%) and that the majority of 
tumors detected are clinically significant (81–93%)
Potential methodological differences between studies 
During MRI-targeted prostate biopsies the operator is privy 
both to mpMRI and ultrasound findings and has a real-time 
image of the lesion during the biopsy process. This has 
shown significant advantages over systematic TRUS-GB (29). 
However, there is considerable heterogeneity in the study 
designs reported in the literature. This is due to a number 
of differences that range from the definition of clinically 
significant disease to the mpMRI protocols used.
The definition of clinically significant prostate cancer is 
often based on the Epstein criteria (PSA density >0.15; more 
than a third of biopsy cores positive; more than 50% of 
involvement of any core) (30) or the d’Amico classification 
(Gleason score >6; PSA >10 ng/mL; > stage T1) (31). These 
were defined in the setting of a systematic biopsy. Of note, 
these classifications were derived from a previous analysis 
by Stamey et al. (32) where the tumor volume threshold 
of 0.5 cm3 for insignificant prostate cancer was obtained 
from 139 consecutively sampled radical cystoprostatectomy 
specimens. The Authors found that 55/139 men (40%) had 
incidental prostate cancer and—basing on epidemiological 
data—suggested that tumors measuring <0.5 cm3 were 
unlikely to reach a clinically significant size within a 
man’s life.
Due to the introduction of MRI-targeted biopsies, 
the definition of clinically significant prostate cancer has 
been changing and a number of new definitions have been 
proposed, though none have been widely recognized so far 
(18,33,34).
The true prevalence of prostate cancer in any given 
population is another confounding factor when assessing 
which technique is the best to assess the prevalence of 
clinically significant prostate cancer. For example, a 
screening population will have a lower prevalence of disease 
if compared to an unscreened population, or a selected 
group of men with a prior positive biopsy. Some studies on 
MRI-targeted biopsies are focused only on biopsy-naïve 
men with a raised PSA (primary biopsy) whilst others only 
on those men with a previous biopsy, regardless of the 
presence of prostate cancer (secondary biopsy).
The accuracy of mpMRI scans is another potential 
methodological issue, as studies not complying to the 
ESUR guidelines (8) could result in a lower detection rate 
of cancer at imaging.
The accuracy of biopsy sampling is also important; 
histologic information from MRI-targeted biopsies tends 
to show longer cancer core length and higher Gleason sum 
than TRUS-GB, due to the tendency to target the center of 
a tumor which tends to have the highest grade disease (35). 
Vargas et al. (36) reported that 20% of a group of 388 low-risk 
men had their cancers upgraded through the use of mpMRI 
and confirmatory biopsy.
In addition, because multiple cores are directed at a 
highly suspicious area, it is common to get a higher absolute 
number and proportion of positive cores than when the 
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intention is to sample the gland in a systematic manner. 
This could result in different risk stratification of men, if a 
risk stratification system based on standard biopsy is used. 
Evidence acquisition
In this paper, we look at each of the three techniques of 
MRI-targeted biopsy and report those studies which have 
compared outcomes of using more than one technique. We 
searched MEDLINE/PubMed for manuscripts published up 
to November 2016. The search terms used were (cognitive 
registration OR visual registration OR fusion biopsy OR 
in-bore biopsy OR targeted biopsy) AND (prostate cancer 
OR prostate adenocarcinoma OR prostate carcinoma OR 
prostatic carcinoma OR prostatic adenocarcinoma) AND 
(MRI OR NMR OR magnetic resonance imaging OR 
mpMRI OR multiparametric MRI).
If it was not clear from the abstract whether the paper 
might contain relevant data, the full paper was assessed. 
Overall, 731 publications were found. The literature 
search and study pre-selection is graphically displayed in 
Figure 2. As the majority of studies assessed one MRI-
targeting technique against standard biopsies this is also 
discussed. 
Evidence synthesis
Among the 189 reports which were assessed in full, 57 (30%) 
used visual registration, 108 (57%) used software assisted 
registration and 13 (7%) used in-bore MRI-targeted 
biopsies, with 11 (6%) reporting a comparison of different 
techniques. 
Visual registration compared to standard biopsy
In a study by Park et al. (21) of biopsy-naïve men randomized 
to standard TRUS (n=41) or mpMRI-targeted biopsies 
(n=44), prostate cancer was detected in 30% (13 of 44) 
of the mpMRI-targeted group compared with 10% (4 of 41) 
of the standard TRUS biopsy group. The Authors 
concluded that in men with rising PSA and no previous 
biopsy, the use of mpMRI before TRUS-GB contributed to 
the detection of prostate cancer. 
Haffner et al. (17) compared MRI-targeted biopsy 
with systematic biopsy in 555 men, and reported that 
the detection accuracy of significant prostate cancer 
by targeted biopsies is significantly higher than that by 
extended systematic biopsies. Moreover, 13% of clinically 
insignificant cancers would have been avoided with the use 
Figure 2 Flow diagram showing the outcome of the initial searches resulting in the full studies included in the review. MRI, magnetic 
resonance imaging.
731 records identified
308 records for full review
189 full papers reporting at least one
MRI/targeted biopsy technique
108 reports: fusion
57 reports: visual registration
13 reports: in-bore
11 reports comparing two 
or more techniques
66 review articles
20 full text not in English
33 technical reports
423 not relevant to 
research question
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of targeted biopsy alone.
Watanabe et al. (37) have reported interesting results 
on the use of DW-MRI from mpMRI to guide MRI-
targeted biopsies. The population comprised 1,448 men 
suspected of having prostate cancer based on PSA level, and 
was split into two groups. Group A (890 patients with low 
apparent diffusion coefficient—ADC—lesions on mpMRI) 
underwent both targeted and systematic biopsies, whereas 
group B (558 patients with no ADC lesion on mpMRI) 
underwent systematic biopsies. Overall prostate cancer 
detection was 70.1% for group A compared with 13.1% 
for group B (P<0.001). Interestingly, the use of ADC maps 
resulted in the significantly greater cancer detection rates 
observed in group A.
Software-assisted fusion registration compared to 
systematic biopsy
Pinto et  al .  (22) have compared standard 12-core 
TRUS biopsy with MRI/TRUS fusion biopsy with an 
electromagnetic tracking device in 101 men. Prostate cancer 
was identified in 55 out of 101 men and MRI/TRUS fusion 
detected more cancer per core than systematic 12-core TRUS 
biopsy for patients with low, moderate and high suspicion 
of cancer on mpMRI. The targeted approach required a 
mean of 2.6 cores compared with 12 for the standard series, 
potentially reducing the detection of insignificant disease.
Another research group (38) performed MRI/TRUS 
fusion biopsies, followed by conventional standard 
transrectal or transperineal biopsies, in 85 men with a 
previous negative biopsy. Prostate cancer was detected in 
52 out of 85 men (61%). The evaluation of biopsy cores 
showed that the detection rate per core was significantly 
higher in MRI/TRUS fusion biopsy (62/192 positive biopsy 
cores; 32%) compared to standard biopsy (75/833 positive 
cores; 9%) (P< 0.01). 
Hadaschik et al. (39) investigated the use of transperineal 
MRI/US fusion biopsies in addition to standard transperineal 
cores in a population of 106 men; prostate cancer was 
detected in 63 out of 106 men (59%), with cancer detection 
per core rates of 25% (101/410 positive cores) versus 9% 
(179/2,051 positive cores) for the MRI-targeted and standard 
cores, respectively. 
The use of MRI/TRUS fusion biopsy has been shown 
to be of particular help in sampling midline lesions (40), 
and to rule out the presence of prostate cancer on a second 
MRI/TRUS fusion biopsy in mpMRI visible lesions initially 
found to be pathologically benign on first MRI/TRUS 
fusion biopsy (41).
Cool et al. (42) have recently evaluated the clinical 
benefit of MRI/TRUS fusion biopsy over systematic biopsy 
between first-time (n=50) and repeat prostate biopsy (n=50) 
men with prior atypical small acinar proliferation (ASAP). 
They concluded that, whilst the detection rate of clinically 
significant disease was higher in the first time biopsy group 
(17/50) compared to the biopsy after ASAP group (7/50), 
the addition of MRI/TRUS fusion biopsy had greater 
clinical utility in the repeat biopsy group, as fusion detected 
more cancers missed by standard biopsy. This is in keeping 
with other series, where at first biopsy many tumors will be 
detected on both standard and targeted biopsy, but when 
men are re-biopsied after an initial biopsy negative for 
cancer the tumors are detected on targeted biopsy rather 
than repeat biopsy. This suggests that targeting corrects 
the systematic error of missing midline, anterior, apical and 
extreme basal tumors, more often than the random error of 
missing a peripheral zone tumor. 
In-bore registration
In a systematic review, Overduin et al. (28) have reported 
that the majority of tumors detected by this technique are 
clinically significant (81–93%). They concluded that in-
bore MRI-guided biopsy is an accurate and safe diagnostic 
tool to detect clinically significant prostate cancer but, due 
to the limited general availability, this procedure should be 
reserved for specific patients.
There is growing evidence that missed cancer rates of in-
bore MRI guided biopsies are low, ranging from 6% to 10% 
(42,43). 
In a study by Hambrock et al. (14), specimens obtained 
by in-bore biopsies were found to be highly representative 
of true tumor grade, exactly matching prostatectomy 
histopathology in 88% of cases. 
A recent  s tudy by Schimmöller  e t  a l .  (43)  has 
retrospectively evaluated the utility of two targeted biopsy 
cores per mpMRI-lesion within in-bore guided biopsy 
in 290 men. They demonstrated that taking only one 
biopsy core per lesion using the in-bore approach does not 
significantly affect the final Gleason classification when 
compared to 2 cores. In almost 90% of the men included in 
the study there was no upgrading of the Gleason score by 
the second targeted biopsy core of a particular intraprostatic 
lesion. In only 2% there was an upgrade to a clinical 
significant prostate cancer (Gleason score ≥4+3=7).
Felker et al. (44) have reported interesting results on a 
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cohort of 461 men (381 with no previous prostate cancer 
and 80 under active surveillance), who underwent in-bore 
magnetic resonance biopsy. With a mean of 1.7 sampled 
targets per gland, the Authors concluded that in-bore 
targeted biopsy appears most useful in men with high 
or very high suspicion lesions, with detection rates for 
clinically significant disease of 43% and 84%, respectively.
Studies comparing multiple MRI-targeted biopsy 
techniques
Eleven studies were identified which compared two different 
MRI-targeting techniques. One study was a simulation study, 
and two studies selected men for one technique or another 
in a non-randomised fashion, and are described below. 
The eight remaining studies are summarized in Table 1 
and Table S1. Only two studies (47,52) investigated a totally 
biopsy-naïve cohort of men (n=451). All mpMRI scans were 
performed on either a 1.5T or 3T scanner and had T2-
weighted scans, DWI and DCE. In the study by Lee et al. (45) 
12% of men did not have a DCE study. Standard TRUS 
biopsy was used as an additional comparator in 6 studies. 
Two studies compared biopsy techniques across 
different men biopsied at different time periods in the same 
institution, rather than comparing techniques in the same 
men, or randomizing men to one approach or another. 
With a sequential design, it is possible that the selection 
criteria for men having an MRI or biopsy may differ 
between groups, or that there may be a learning curve effect 
both in terms of MRI and biopsy, over time. 
Delongchamps and colleagues (52) compared the 
accuracy of targeted biopsies in 391 patients using visual 
registration (n=127), rigid (n=131) and elastic (n=133) fusion, 
over three consecutive time periods. The positive mpMRI 
rate increased over the three time periods, with a rate of 
54/127 (42%) in the first cohort who had visual registration, 
78/131 (59%) in the second cohort who had rigid registration 
and 82/133 patients (62%) in the third cohort who had 
elastic registration. Clinically significant cancer on mpMRI-
targeted biopsies was found in 18/127 (14%), 33/131 (19%) 
and 27/133 (20%) of each cohort respectively. They reported 
that visual registration did not improve cancer detection over 
systematic biopsies (P=0.66) and that there was a significantly 
increased cancer detection rate with rigid (P=0.006) and 
elastic (P=0.001) fusion biopsies when compared with random 
biopsies, with the added value of requiring fewer cores and 
an associated decreased detection of clinically insignificant 
prostate cancer.
The higher detection rate in the later cohorts of rigid 
and elastic fusion techniques could be ascribed to the more 
accurate delineation of mpMRI suspicious lesions, although 
the lower positive MRI rate in the first group may be a 
factor. The Authors concluded that mpMRI-targeted biopsy 
alone provided a significantly higher cancer detection rate 
than random biopsies and that mpMRI-targeted biopsies 
increased the detection rate of high Gleason score cancer, 
while decreasing the detection rate of small and well 
differentiated tumors.
Mouraviev and colleagues (53) compared mpMRI targeted 
prostate biopsy in 32 men using visual registration (n=9), 
software-assisted registration (n=13) and in-bore biopsy 
(n=10). This is the only report comparing all three techniques, 
but the population seems to differ between the groups, which 
limits the applicability of the findings. The cancer detection 
rate was 33% (3/10 men) for visual registration and 46% 
(6/13 men) for software-assisted registration (P=0.005), and 
80% (8/10 men) for in-bore biopsy (P=0.005 when compared 
to software-assisted registration). However, the Authors 
reported that the majority of men undergoing in-bore 
biopsy (7/10) had a previously diagnosed prostate cancer on 
TRUS-guided 12-core biopsy. In addition, the detection rates 
for visually targeted and fusion biopsies are low compared to 
other series.
Cool and colleagues reported a retrospective, simulation 
study performed using a validated TRUS prostate biopsy 
device (54). The simulator used a tracking system to 
monitor the 3D position of the probe within a phantom; 
3D TRUS and mpMRI images were fused together and 
shown within the simulator, where a biopsy could be taken 
by targeting the probe. The initial population included 
100 men (50 biopsy naive and 50 with a previous negative 
biopsy or atypical small acinar proliferation). After defining 
clinically significant prostate cancer as any core with a 
Gleason score ≥7 or more than 50% tumor involvement 
in the core, the final population consisted of 20 men with 
clinically significant on mpMRI targeted cores, with a total 
of 25 clinically significant tumors. Three different operators 
performed simulated biopsies on all 25 lesions using three 
different methodologies (2D TRUS, 3D TRUS and MRI-
TRUS fusion), for a total of 225 targeted biopsies (75 for 
each technique). The Authors concluded that fusion biopsy 
(75/75; 100%) would be significantly more accurate than 
2D (36/75; 48%) and 3D (34/75; 45%) visual registration 
under TRUS guidance (P<0.001).
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Visual registration vs. software assisted registration of 
MRI and ultrasound images
Four studies including a total of 556 patients were not able 
to demonstrate significant differences between the two 
techniques in clinically significant cancer detection, using 
definitions of clinically significant cancer ranging from 
Gleason ≥3+4 to maximum cancer core length of 4 mm. 
(45,48,49,55).
Of note, Puech et al. (55) reported that of 95 men in 
the study there was a group of 68 men with 79 targets on 
MRI. Positivity for cancer per target was 47% for visually 
targeted biopsy and 53% for fusion biopsy. The Authors 
demonstrated no difference in cancer detection between 
techniques when they looked at subgroups of posterior, 
anterior or smallest imaging targets.
Wysock et al. (49) prospectively reported the two 
targeting techniques in 125 consecutive men, with a total 
of 172 mpMRI-suspicious lesions that were targeted using 
software assisted registration. Targets were then blinded, 
and a second operator took two visually targeted cores and a 
12-core biopsy.
Overall cancer detection rate per patient was 45 (36%) 
and 40 (32%), and Gleason sum ≥7 cancer detection 
rate was 29 (23.2%) and 24 (19.2%) by fusion and visual 
registration, respectively (P=0.36, P=0.27). Also this 
study demonstrated no difference in cancer detection rate 
between the two techniques, but a trend toward improved 
cancer detection rate was observed overall and in all subsets, 
suggesting a need for a larger sample size.
Lee et al. (45) reported the difference in the detection of 
high-grade (Gleason ≥7) and any grade cancer between the 
two techniques in 286 men. The difference between fusion 
and visually registered biopsy was –1.4% (P=0.6) for high-
grade cancer (74 vs. 78 men, respectively) and 3.5% for any 
grade cancer (P=0.2), neither of which were statistically 
significant. Interestingly, the Authors found that an MRI/
TRUS fusion biopsy could detect tumors that are difficult 
to be visually targeted (i.e., those in the transition zone) 
and they concluded that combining both techniques may 
improve prostate cancer detection. 
Similar results have been reported by Valerio and 
colleagues (48) in a cohort of 50 men undergoing visual, 
fusion and systematic transperineal biopsies. The Authors 
found that the detection rate of clinically significant prostate 
cancer was 32/50 (64%), 34/50 (68%) and 38/50 (76%) 
respectively and concluded that combining the two targeting 
approaches could minimize missed cancer rates, with a 
detection similar to systematic biopsies. Transperineal 
template prostate mapping was performed using the 20-zone 
modified-Barzell template, regardless of the position of the 
targets and the biopsy density previously employed with 
the targeted strategies. Transperineal template prostate 
biopsies identified 10 men (20%) and 8 men (16%) with 
clinically significant disease that was missed or undergraded 
by visually directed targeted biopsy and by software-based 
targeted biopsy, respectively.
Other studies did report a difference between the 
different MRI-targeted approaches, with three studies (total 
341 men) reporting a difference between techniques, with 
two finding higher cancer detection with software assisted 
biopsies, and one for visually registered biopsies. 
Oberlin et al. (46) analyzed a cohort of 231 men 
undergoing fusion (n=81) or visual MRI-targeted biopsy 
(n=150). The Authors concluded that the overall detection 
rate of cancer was significantly higher in the fusion cohort 
(48.1%) compared to the visual registration group (34.6%) 
(P=0.04).
Oderda et al. (50) retrospectively evaluated 50 men 
(16 with a previous negative biopsy and 5 with a previous 
negative transurethral resection of the prostate) undergoing 
fusion (n=25) or visually registered (n=25) MRI-targeted 
biopsy. The cancer detection rate of mpMRI targets was 
significantly higher in fusion (59%) than visually registered 
biopsies (27%) (P=0.03).
Pepe et al. (47) reported on the detection rate for 
clinically significant prostate cancer of transperineal (visually 
registered) vs. transrectal (rigid fusion) MRI-guided 
biopsies, comparing these two techniques to transperineal 
saturation biopsy in 60 men. Transperineal visually targeted 
biopsy detected a greater percentage of clinically significant 
prostate cancer of the anterior zone when compared to 
transrectal fusion biopsy (93.3% vs. 25% respectively, 
P<0.001).
One might argue that the anatomical approach could 
have influenced these results, as a transperineal approach 
permits the operator to sample the anterior zone of the 
gland more easily. 
MRI/TRUS fusion biopsy vs. in-bore
We found only one published study which directly 
compared an MRI-ultrasound method with an in bore 
approach. This study, by Arsov et al. (51), compared in-
bore and software-assisted fusion biopsies in men with 
prior negative biopsies. The Authors investigated 210 men 
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(106 undergoing in-bore and 104 fusion plus TRUS biopsies) 
and observed that detection rates for clinically significant 
prostate cancer (Gleason ≥3+4) (29% vs. 32%; P=0.7) and 
the highest percentage tumor involvement per biopsy core 
(48% vs. 42%; P=0.4) were similar between the arms. 
Future studies
It is important to mention that there is also an ongoing 
large randomized controlled trial (planned recruitment of 
675 patients) comparing all three techniques in men with 
a persistent clinical suspicion of prostate cancer and at 
least one negative TRUS biopsy (56). The hypothesis of 
this trial is that MRI/TRUS fusion biopsy demonstrates a 
similar cancer detection rate of prostate cancer compared 
to in-bore biopsy, whilst demonstrating an increased cancer 
detection rate compared to visual TRUS biopsy (56). 
Conclusions
Ideally, the optimal biopsy technique should have the 
highest detection rate of clinically significant prostate 
cancer, while simultaneously having the lowest detection 
rate of clinically insignificant disease. Currently there is no 
consensus on which type of MRI-targeted biopsy performs 
better in a given setting. Although there have been studies 
supporting each of the three techniques, substantial 
differences in methodology and reporting the findings 
make it difficult to reliably compare their outcomes. 
The economic implications of using software assisted 
registration or in-bore registration should be borne in mind 
when choosing an approach. 
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Table S1 Details of magnetic resonance imaging and biopsy techniques, and histologic outcomes in the full studies included in the review
Study (ref.) Type of study
Allocation to biopsy 
methods
Inclusion criteria
Comparator (standard 
test)
Sampling route
No. of patients for the 
analysis
Previous biopsy
MRI MRI-targeted biopsy
Magnet strength Endorectal coil Sequences Navigational system for biopsy Targeted cores per lesion
Overall prostate cancer 
detection rate per patient
Overall prostate cancer detection rate 
per core/per target
Definition of clinically significant disease
Detection rate clinically significant 
disease per patient
Detection rate clinically significant disease 
per core/per target
Significant difference between MRI-targeted 
techniques
Arsov et al. (51) Prospective Randomized Negative TRUS-biopsy and 
persistent rising PSA
In bore vs. fusion +TRUS Transrectal 210 Negative TRUS biopsy 3T No T2, DWI, DCE (I) In bore (106/210; 50%); (II) fusion + TRUS 12 
cores (104/210; 50%)
2 (for each technique) (I) 39/106 (37%); (II) 
35/104 (34%) only fusion
(I) 123/595 (21%); (II) 210/1,808 (12%) Gleason ≥3+4 (I) 31/106 (29%); (II) 27/104 (26%) only 
fusion
NR No
Lee et al. (45) Prospective Sequential Lesion scoring ≥3 at MRI NR Transrectal 286 75/286 biopsy naive; 186/286 positive 
biopsy; 16/286 negative biopsy
1.5T/3T No T2, DWI, (DCE) Visual registration ((I) + fusion ((II) in all 2 (for each technique) NR (I) 131/396 (33%); (II) 145/396 (37%) Gleason ≥3+4 (I) 78/286 (27%); (II) 74/286 (26%) 90/396 (25%); 82/396 (21%) No, although VR performed better at the base, 
and FB better in the TZ
Oberlin et al. (46) Retrospective Randomized Rising PSA, abnormal DRE, 
active surveillance
TRUS 12 cores Transrectal 231 NR 3T NR T2, DWI, DCE (I) Visual registration (150/231; 65%); (II) fusion 
(81/231; 35%)
1 to 3 (I) 52/150 (35%); (II) 
39/81 (48%)
NR Gleason ≥3+4 (I) 25/150 (17%); (II) 24/81 (30%) NR MRI-fusion has a higher overall detection rate 
than visual registratiom
Pepe et al. (47) Prospective Sequential Negative DRE, rising PSA Transperineal saturation 
biopsy (28 to 34 cores)
Transperineal (visual registration) 
+ Transrectal (fusion)
60 men with clinically 
significant cancer from a 
cohort of 200 men having 
repeat biopsy
Repeat saturation transperineal prostate 
biopsy
3T No T2, DWI, DCE TP Visual registration ((I) +TR fusion ((II) in all 4 (for each technique) NR NR Gleason ≥3+4 and/or >2 positive cores (I) 56/60 (93%); (II) 40/60 (67%) NR Transperineal visual registration biopsy has a 
higher detection rate than transrectal fusion 
biopsy of the anterior zone
Puech et al. (55) Prospective Sequential Rising PSA and suspicious 
lesion at MRI
TRUS 12 cores Transrectal 95 65/95 biopsy naïve; 30/95 prior negative 
biopsy
1.5T No T2, DWI, DCE Visual registration ((I) + fusion ((II) in 68 men 
(remaining 27 had 1 technique only)
2 (for each technique) 72/95 (76%) On 68 men, with 79 MR imaging 
targets: (I) 37/79 (47%); (II) 42/79 
(53%)
Cancer core length ≥3 mm or Gleason ≥3+4 65/95 (68%) Possible only on 33/79 MR imaging 
targets: (I) 20/33 (61%); (II) 21/33 (64%)
No
Valerio et al. (48) Prospective Sequential Suspicious lesions at MRI Transperineal template 
(22 to 41 cores)
Transperineal 50 5/50 biopsy naïve; 5/50 prior negative 
biopsy; 40/50 prior positive biopsy (of which 
8 post RT failure)
1.5/3T No T2, DWI, DCE Visual registration ((I) + fusion ((II) in all (I) 3 to 6; (II) 3 to 5 (I) 36/50 (72%); (II) 37/50 
(74%)
(I) 41/79 (52%); (II)46/79 (59%) Gleason score ≥4 and/or maximum cancer core 
length >4 mm
(I) 32/50 (64%); (II) 34/50 (68%) (I) 35/79 (44%); (II) 41/79 (52%) No
Wysock et al. (49) Prospective Sequential Suspicious lesions at MRI TRUS 12 cores Transrectal 125 67/125 biopsy naïve; 34/125 negative; 
24/125 low-risk cancer
3T No T2, DWI, DCE Visual registration ((I) + fusion ((II) in all 2 (for each technique) (I) 40/125 (32%); (II) 
45/125 (36%)
(I) 46/172 (27%); (II) 55/172 (32%) Gleason ≥3+4 (I) 24/125 (19%); (II) 29/125 (23%) (I) 26/172 (15%); (II) 35/172 (20%) No
Oderda et al. (50) Retrospective Randomized Clinical suspicion and 
suspicious lesion at MRI
TRUS (variable number 
of cores)
Transrectal 50 (I) 14/25 biopsy naïve, 8/25 negative, 3/25 
negative TURP; b) 15/25 biopsy naïve, 8/25 
negative, 2/25 negative TURP
1.5T No T2, DWI, DCE (I) Visual registration (25 men); (II) elastic fusion 
(25 men)
(I) 2.6 (mean); (II) 3.6 
(mean)
(I) 10/25 (40%); (II) 16/25 
(63%)
(I) 7/26 (27%); (II) 16/27 (59%) Gleason ≥3+3 and ≥2 positive cores (I) 8/25 (32%); (II) 12/25 (48%) (I) 6/26 (23%); (II) 10/27 (37%) Elastic fusion has a higher detection rate than 
visual registration
DRE, digital rectal examination; MRI, magnetic resonance imaging; TRUS, transrectal ultrasound; DWI, diffusion-weighted imaging; DCE, dynamic contrast enhanced; NR, not reported; TURP, transurethral resection of the prostate; RT, radiotherapy; PSA, prostate specific antigen; VR, visual registration; FB, fusion biopsy; TZ, transitional zone; TP, transperineal; TR, transrectal.
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